The above reviews our developing knowledge on the nature of B cell-specific interleu-kins. It may be anticipated that in the next several years, considerable progress will be made in understanding the physicochemical properties of these factors, their time and nature of action, and the nature of their receptors. Such information should lead to a new physiologically based pharmacology for manipulation of antibody responses in human disease and in response to vaccines.